{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+100Mg+Tablet",
    "query": {
      "intervention": "Spironolactone 100Mg Tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+100Mg+Tablet&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T02:02:47.755Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07043634",
      "title": "A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bioavailability Heathy Volunteers"
      ],
      "interventions": [
        {
          "name": "FDC (24 mg ER torsemide and 30 mg Spironolactone) without food",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "FDC (24 mg ER torsemide and 30 mg Spironolactone) with food",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Sarfez Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-06-15",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 1,
      "location_summary": "Vienna, Virginia",
      "locations": [
        {
          "city": "Vienna",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07043634"
    },
    {
      "nct_id": "NCT07041281",
      "title": "Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Preeclampsia",
        "Gestational Hypertension"
      ],
      "interventions": [
        {
          "name": "spironolactone 25 mg orally once daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 204,
      "start_date": "2025-10-16",
      "completion_date": "2029-03-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07041281"
    },
    {
      "nct_id": "NCT03048825",
      "title": "Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ST Elevation Myocardial Infarction",
        "Non ST Elevation Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Colchicine",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "SYNERGY Bioabsorbable Polymer Drug-Eluting Stent",
          "type": "DEVICE"
        },
        {
          "name": "Colchicine-Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone-Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Population Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7264,
      "start_date": "2018-02-01",
      "completion_date": "2024-08-09",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 11,
      "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Munster",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03048825"
    },
    {
      "nct_id": "NCT05010707",
      "title": "Transgender Estradiol Affirming Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transgenderism"
      ],
      "interventions": [
        {
          "name": "Transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Pro-thrombotic markers",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Metabolic markers",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Hormone Profile",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Daily Sublingual Tablet",
          "type": "DRUG"
        },
        {
          "name": "BID Sublingual Tablet",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "MALE",
        "summary": "18 Years to 30 Years · Male only"
      },
      "enrollment_count": 39,
      "start_date": "2021-08-02",
      "completion_date": "2024-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05010707"
    },
    {
      "nct_id": "NCT03071263",
      "title": "Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperkalemia",
        "Resistant Hypertension"
      ],
      "interventions": [
        {
          "name": "Patiromer",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relypsa, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 295,
      "start_date": "2017-01-23",
      "completion_date": "2018-11-27",
      "has_results": true,
      "last_update_posted_date": "2021-05-12",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • Miami Lakes, Florida • Chicago, Illinois",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071263"
    },
    {
      "nct_id": "NCT07223502",
      "title": "A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension (HTN)"
      ],
      "interventions": [
        {
          "name": "Combination Product: FDC of spironolactone and ER torsemide",
          "type": "DRUG"
        },
        {
          "name": "Combination Product: Stabilized doses of loop diuretic and finerenone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarfez Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-05-01",
      "completion_date": "2026-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 1,
      "location_summary": "Vienna, Virginia",
      "locations": [
        {
          "city": "Vienna",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223502"
    },
    {
      "nct_id": "NCT02901184",
      "title": "Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Standard care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Uppsala University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2017-11-23",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 38,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02901184"
    },
    {
      "nct_id": "NCT01855334",
      "title": "L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "L-arginine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-09",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2017-05-04",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01855334"
    },
    {
      "nct_id": "NCT00860340",
      "title": "Hemodynamic Effects of Spironolactone in Patients With Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Toledo Health Science Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2003-02",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2014-12-10",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00860340"
    },
    {
      "nct_id": "NCT00811486",
      "title": "Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Right Heart Failure",
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Spironolactone and conivaptan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-01",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-28",
      "last_synced_at": "2026-09-24T02:02:47.755Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811486"
    }
  ]
}